Fig. 1: Trial profiles of the 53 patients.

RECIST response evaluation criteria in solid tumors, RCCEP reactive cutaneous capillary endothelial proliferation, TPF docetaxel, cisplatin, and capecitabine, CR complete response, PR partial response, SD stable disease, PD progress disease. Source data are provided as a Source Data file.